DE69111232D1 - 5-benzyl barbitursäurederivate. - Google Patents

5-benzyl barbitursäurederivate.

Info

Publication number
DE69111232D1
DE69111232D1 DE69111232T DE69111232T DE69111232D1 DE 69111232 D1 DE69111232 D1 DE 69111232D1 DE 69111232 T DE69111232 T DE 69111232T DE 69111232 T DE69111232 T DE 69111232T DE 69111232 D1 DE69111232 D1 DE 69111232D1
Authority
DE
Germany
Prior art keywords
acid derivatives
barbituric acid
benzyl
toxicity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69111232T
Other languages
English (en)
Other versions
DE69111232T2 (de
Inventor
Fardos Naguib
Kouni Mahmoud El
Raymond Panzica
Sungman Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University Research Foundation Inc
Original Assignee
Brown University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc filed Critical Brown University Research Foundation Inc
Publication of DE69111232D1 publication Critical patent/DE69111232D1/de
Application granted granted Critical
Publication of DE69111232T2 publication Critical patent/DE69111232T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69111232T 1990-04-12 1991-04-12 5-benzyl barbitursäurederivate. Expired - Fee Related DE69111232T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/508,363 US5141943A (en) 1990-04-12 1990-04-12 5-benzyl barbiturate derivatives
PCT/US1991/002522 WO1991016315A1 (en) 1990-04-12 1991-04-12 5-benzyl barbiturate derivatives

Publications (2)

Publication Number Publication Date
DE69111232D1 true DE69111232D1 (de) 1995-08-17
DE69111232T2 DE69111232T2 (de) 1995-12-21

Family

ID=24022452

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69111232T Expired - Fee Related DE69111232T2 (de) 1990-04-12 1991-04-12 5-benzyl barbitursäurederivate.

Country Status (10)

Country Link
US (1) US5141943A (de)
EP (1) EP0526537B1 (de)
JP (1) JP3001972B2 (de)
AT (1) ATE124936T1 (de)
AU (1) AU7776891A (de)
CA (1) CA2080343C (de)
DE (1) DE69111232T2 (de)
DK (1) DK0526537T3 (de)
ES (1) ES2077850T3 (de)
WO (1) WO1991016315A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
GB9214720D0 (en) * 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
JPH08503699A (ja) * 1992-12-08 1996-04-23 プロ − ニューロン，インコーポレーテッド 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US5889013A (en) * 1994-02-28 1999-03-30 Sunkyong Industries Co., Inc. Pyrimidine acyclonucleoside derivatives
MX9700109A (es) * 1994-07-01 1997-04-30 Pro Neuron Inc Precursores nucleotidos de pirimidina para el tratamiento de inflamaciones sistemicas y hepatitis inflamatoria.
US7198190B2 (en) * 1997-03-12 2007-04-03 Dodge Juhan Identification device having reusable transponder
JPH11279157A (ja) * 1998-03-27 1999-10-12 Hoechst Marion Roussel Kk バルビツール酸誘導体およびそれらからなる骨・軟骨疾患予防・治療薬
WO1999061427A1 (fr) * 1998-05-26 1999-12-02 Rimma Iliinichna Ashkinazi Derives n-substitues d'acide 5-oxyiminobarbiturique
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
DE69941586D1 (de) 1998-07-31 2009-12-03 Massachusetts Inst Technology Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
CN101896119A (zh) * 2007-11-02 2010-11-24 麻省理工学院 尿苷饮食添加顺应性方法及其用途
WO2009114325A2 (en) 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
RU2581467C1 (ru) * 2015-04-06 2016-04-20 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Антидот окиси углерода
DE102016011954A1 (de) * 2016-10-07 2018-04-12 Merck Patent Gmbh Barbitursäurederivate als Selbstbräunungssubstanzen
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
WO2024200612A1 (en) * 2023-03-30 2024-10-03 Université de Lausanne Inhibitors of uridine catabolism and/or transport for therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3464990A (en) * 1967-02-27 1969-09-02 Hoffmann La Roche Barbituric acid derivatives substituted in the five position
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2627076A1 (de) * 1976-06-16 1977-12-29 Max Planck Gesellschaft Mittel zur inhibierung des zellwachstums
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
US4093715A (en) * 1977-04-28 1978-06-06 Research Corporation 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof
US4128639A (en) * 1977-12-14 1978-12-05 Research Corporation Nitrosourea analogs of thymidine
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4230698A (en) * 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4681933A (en) * 1986-05-01 1987-07-21 University Of Georgia Research Foundation, Inc. 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents

Also Published As

Publication number Publication date
CA2080343C (en) 2001-10-23
ES2077850T3 (es) 1995-12-01
ATE124936T1 (de) 1995-07-15
DK0526537T3 (da) 1995-10-02
CA2080343A1 (en) 1991-10-13
US5141943A (en) 1992-08-25
AU7776891A (en) 1991-11-11
WO1991016315A1 (en) 1991-10-31
JPH05506240A (ja) 1993-09-16
EP0526537B1 (de) 1995-07-12
DE69111232T2 (de) 1995-12-21
EP0526537A1 (de) 1993-02-10
JP3001972B2 (ja) 2000-01-24

Similar Documents

Publication Publication Date Title
DE69111232D1 (de) 5-benzyl barbitursäurederivate.
DK0545966T3 (da) Phospholipidderivater af nucleosider, deres fremstilling samt deres anvendelse som anti-virale lægemidler
DK0465297T3 (da) 9-Purinylphosphonsyre-derivater
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
MX9303711A (es) Nucleosidos de pirimida sustituida que tienen actividad anti-tumoral y anti-viral y composicion farmaceutica que los contiene.
DE60101223D1 (de) Antivirale pyrimidin nucleoside derivate
PT100199A (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
NL300247I2 (nl) 2-Halogeen-9-(2-desoxy-2-fluor-bêta-D-arabinofuranosyl)-adeninenucleosiderivaten.
DK0805683T3 (da) 5-fluor-2',3'-umættet-pyrimidinnukleosider
PT1066269E (pt) Derivados de 1,3,5-triazina trissubstrituidos para o tratamento de infeccoes por hiv
BR0113146A (pt) Derivados de prolina e uso destes como drogas
NO2000007I1 (no) Itraconazol inklusjonskompleks med hydroksypropyl-ß -cyklodekstriner
ATE137242T1 (de) Kovalente-ther lipidnukleosid-konjugate
RU93045710A (ru) Противовирусная нуклеозидная композиция, способ ее получения и способ лечения
ES2074719T3 (es) Derivados de nucleosido de pirimidina.
DK0522173T3 (da) 4-Desoxy-4-epipodophyllotoxinderivater eller farmaceutisk acceptable salte deraf
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
FR2687678B1 (fr) Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
FI912963A (fi) Hjaernverksamheten oekande pyrimidinylderivat.
IT8821570A0 (it) Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
NO913659L (no) Hemming av hiv ved anvendelse av synergistiske kombinasjoner av nukleosidderivater.
ATE208788T1 (de) Pyrimidin nukleosid derivate
KR930701470A (ko) 누클레오시드의 인지질 유도체, 이것의 제조방법 및 항바이러스제로서의 사용
IL166484A0 (en) Myriaporone derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee